XM nie świadczy usług obywatelom Stanów Zjednoczonych.
I
I

IQVIA


Wiadomości

Law firm Hogan Lovells taps FTC antitrust lawyer as agency probes more deals

UPDATE 1-Law firm Hogan Lovells taps FTC antitrust lawyer as agency probes more deals Adds comments from Jennifer Fleury in paragraph 6 By David Thomas Oct 15 (Reuters) - International law firm Hogan Lovells said on Tuesday that it has hired a senior lawyer from the U.S. Federal Trade Commission amid a period of increased antitrust enforcement activity by the agency.
M
I

Law firm Hogan Lovells taps FTC antitrust lawyer as agency probes more deals

Law firm Hogan Lovells taps FTC antitrust lawyer as agency probes more deals By David Thomas Oct 15 (Reuters) - International law firm Hogan Lovells said on Tuesday that it has hired a senior lawyer from the U.S. Federal Trade Commission amid a period of increased antitrust enforcement activity by the agency. Jennifer Fleury joined Hogan Lovells as a partner in its Washington, D.C.
M
I

U.S. Factset, FedEx, Thermo Fisher Scientific

U.S. RESEARCH ROUNDUP-Factset, FedEx, Thermo Fisher Scientific Sept 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Factset, FedEx and Thermo Fisher Scientific on Friday. HIGHLIGHTS * Arthur J. Gallagher & Co. AJG.N : RBC raises target price to $320 from $310 * Factset FDS.N : RBC raises target price to $503 from $464 * FedEx Corp FDX.N : Baird cuts target price to $320 from $340 * IQVIA Holdings Inc IQV.N : Baird
A
A
A
B
D
E
N
X
T
A
D
I
L
P

India's Strides Pharma rises on US FDA nod for drug to treat asthma, lung diseases

BUZZ-India's Strides Pharma rises on US FDA nod for drug to treat asthma, lung diseases ** Shares of Strides Pharma Science SRID.NS rise 2.4% to 1,376.8 rupees ** The pharma products maker's unit gets approval from U.S. Food and Drug Administration for generic version of a drug used to treat chronic asthma and lung diseases like emphysema and bronchitis ** The drug - Theophylline extended-release tablet - has a market size of $11.5 million, as per pharma analytics and research firm IQVIA ** SRID
I

India's Aurobindo Pharma up on FDA nod for product treating menopause condition

BUZZ-India's Aurobindo Pharma up on FDA nod for product treating menopause condition ** Shares of Aurobindo Pharma ARBN.NS rise as much as 2.7% to 1,439.90 rupees, among top gainers in Nifty Pharma index .NIPHARM ** Co on Tuesday received U.S. FDA nod to make and market estradiol vaginal suppositories - a bioequivalent to Novo Nordisk's VAGIFEM - used treat a condition resulting from menopause ** Product has estimated market size of $268 million for the 12 months ended June 2024, as per pharma c
I

Medpace tumbles after bookings disappoint

BUZZ-Medpace tumbles after bookings disappoint ** Medpace's MEDP.O shares down 13.6% premarket to three-mth low $377.91 after clinical contract research organization's bookings miss expectations ** Co late Mon reported Q2 new business awards decreased 4% yr/yr for net book-to-bill ratio (number of orders received to those fulfilled) of 1.04x ** TD Cowen, which rates MEDP "buy", pointed out that consensus called for book-to-bill ratio of 1.23x ** While unclear what drove bookings weakness, some e
I

U.S. Colgate-Palmolive, McKesson, Microsoft

U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft July 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Colgate-Palmolive, McKesson and Microsoft, on Tuesday. HIGHLIGHTS * Colgate-Palmolive Co CL.N : TD Cowen initiates coverage with buy rating; PT $110 * DR Horton Inc DHI.N : JP Morgan raises target price to $180 from $163 * IQVIA Holdings Inc IQV.N : Baird raises target price to $251 from $235 * McKesso
C
H
M
M
T
V
Z
F
A
M
A
C
C
D
I

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change IQVIA Holdings Inc IQV.N +7.7% Lam Research Corp LRCX.OQ +6% ON Semiconductor Corp ON.OQ +5.9% Applied Materials Inc AMAT.OQ +5.8% KLA Corp KLAC.OQ +5.5% Bottom Performers Percent Change CrowdStrike Holdings Inc CRWD.OQ -13.2% Verizon
S
V
K
L
O
U
A
C
I

U.S. STOCKS Walt Disney, Mattel, Tellurian

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, Mattel, Tellurian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq recouped some of the previous week's losses on Monday, as investors reexamined the chances of a second presidential term for Republican nominee Donald Trump after U.S.
G
M
N
S
S
V
A
C
L
U
U
A
G
I
N

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change IQVIA Holdings Inc IQV.N +6.6% ON Semiconductor Corp ON.OQ +4.7% Lam Research Corp LRCX.OQ +4.2% Applied Materials Inc AMAT.OQ +3.9% KLA Corp KLAC.OQ +3.9% Bottom Performers Percent Change CrowdStrike Holdings Inc CRWD.OQ -13.0% Verizo
S
V
K
L
O
U
A
C
I

U.S. STOCKS Verizon Communications, Reddit, Starbucks

BUZZ-U.S. STOCKS ON THE MOVE-Verizon Communications, Reddit, Starbucks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street rose on Monday, regaining some ground after the previous week's declines as investors assessed the odds of a second term for Republican nominee Donald Trump in the November election after President Joe Biden withdrew from the race.
G
N
S
S
V
A
C
L
O
U
U
G
I

IQVIA climbs on annual profit forecast raise

BUZZ-IQVIA climbs on annual profit forecast raise ** Shares of contract research firm IQVIA Holdings IQV.N rise ~6.7% to $239.60, highest since April ** Co forecasts annual adj. profit between $11.10 and $11.30 per share, above its prior range of $10.95 to $11.25 ** Co reports Q2 adj. profit of $2.64/shr vs analysts' average estimate of $2.57/shr -
I

IQVIA Holdings Inc reports results for the quarter ended in January - Earnings Summary

IQVIA Holdings Inc reports results for the quarter ended in January - Earnings Summary IQVIA Holdings Inc IQV.N reported quarterly adjusted earnings of $2.64​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $2.43. The mean expectation of twenty one analysts for the quarter was for earnings of $2.57 per share.
I

IQVIA raises annual profit forecast on improving demand for analytics services

IQVIA raises annual profit forecast on improving demand for analytics services July 22 (Reuters) - Contract research firm IQVIA Holdings IQV.N raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services. Technological and analytical solutions (TAS), IQVIA's second-largest unit, reported a 2.7% rise in second-quarter revenue to $1.50 billion, above estimates of $1.47 billion, according to LSEG data.
I

IQVIA Q2 Adjusted EPS USD 2.64 Vs. IBES Estimate USD 2.57

BRIEF-IQVIA Q2 Adjusted EPS USD 2.64 Vs. IBES Estimate USD 2.57 Jul 22 (Reuters) - IQVIA Q2 net income USD 363 million. Q2 revenue USD 3,814 million vs. IBES estimate USD 3,789 million Q2 adjusted EBITDA USD 887 million vs. IBES estimate USD 884 million Q2 EPS USD 1.97
I

Biden bows out, election bets shift, China cuts

MORNING BID AMERICAS-Biden bows out, election bets shift, China cuts A look at the day ahead in U.S. and global markets from Mike Dolan U.S. President Joe Biden's weekend withdrawal from the White House race can hardly be seen as a big surprise, but it adds some doubts to market bets that Republican challenger Donald Trump is a shoo-in in November's election.
B
C
D
G
G
L
N
N
T
U
U
V
G
J
U
U
U
F
W
I

IQVIA Holdings Inc <IQV.N> expected to post earnings of $2.57 a share - Earnings Preview

IQVIA Holdings Inc expected to post earnings of $2.57 a share - Earnings Preview IQVIA Holdings Inc IQV.N , IQV is expected to show a rise in quarterly revenue when it reports results on July 22 for the period ending June 30 2024 The Durham North Carolina-based company is expected to report a 1.6% increase in revenue to $3.789 billion from $3.73 billion a year ago, according to the mean estimate from 18 analysts, based on LSEG data.The company's guidance on May 2 2024, for the period ended June
I

Novo Nordisk obesity feast no longer a free lunch

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO is going to have to work hard to justify its bulging valuation. The $603 billion obesity drug maker’s shares have more than trebled since 2021 thanks to insatiable appetite for its weight-loss drug.
A
P
R
I



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.